The EASL Liver Cancer Summit 2024 took place in Rotterdam, the Netherlands from 22-24 February and online. 

Primary liver tumours are a major health problem and hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) are leading causes of cancer-related deaths globally. Tumour development is frequently associated with different liver diseases including viral infection, alcohol abuse and metabolic disorders such as NASH and NAFLD. The management of patients with liver cancers has significantly improved over the past years. While in both tumour types immunotherapies are now integral part of systemic treatment, targeted therapies have been specifically introduced in BTC.  Nevertheless, there is still significant room for improvement in the screening, diagnosis and treatment of patients with primary liver cancer.  

To address these critical issues, the Summit gathered key stakeholders engaged in fighting liver cancer, including clinicians, scientists, nurses, patient representatives and industry professionals. 

The programme of the summit showcased the most recent advances in the understanding of the pathogenesis of the two most common primary liver malignancies – hepatocellular and cholangiocellular carcinoma – and debated the state-of-the art in the diagnosis and treatment of patients affected by these primary liver tumours.  

Sincerely, 

Matías Ávila, Valérie Vilgrain, and Arndt Vogel